Gastrointestinal Drugs Market Research Report - Global Forecast till 2025

Global Gastrointestinal Drugs Market Research Report: Information by Drug Class (Acid Neutralizers, Anti-Inflammatory Drugs, Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Biologics and others), Route of Administration (Oral, Parenteral and Rectal), Application (Inflammatory Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, Gastroenteritis and others), Distribution Channel (Retail Pharmacies, Online Pharmacies and Hospital Pharmacies) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

ID: MRFR/Pharma/0115-HCR | February 2021 | Region: Global | 90 pages

Market Scenario


Gastrointestinal Drugs Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 42,180 Million in 2018 and is projected to register a valuation of USD 59,300 Million by 2025, with a CAGR of 4.9% over the forecast period.


The increasing prevalence of gastrointestinal diseases and rising investments and funding in the field of life science research are likely to provide favorable conditions for the growth of the market during the forecast period.


Various other factors, such as the changing lifestyle and increasing number of geriatric individuals, are also expected to propel the growth of the market.


However, high raw material costs and growing presence of counterfeit drugs can hamper market growth over the forecast period.


Segmentation


The global gastrointestinal drugs market is segmented based on drug class, route of administration, application, distribution channel, and region.


The global market for gastrointestinal drugs, by drug class, is segmented into acid neutralizers, anti-inflammatory drugs, antidiarrheal and laxatives, antiemetic and antinauseants, biologics, and others.


Based on route of administration, the market is segmented into oral, parenteral, and rectal.


Based on Application, the market is segmented into inflammatory ulcerative colitis, irritable bowel syndrome, Crohn's disease, celiac disease, gastroenteritis, and others.


Distribution channels are segmented into retail pharmacies, online pharmacies, and hospital pharmacies.


In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The gastrointestinal drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European gastrointestinal drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The gastrointestinal drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gastrointestinal drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Gastrointestinal Drugs Market Share (%), by Region, 2018
 Gastrointestinal Drugs Market


Sources: MRFR Analysis


The Americas dominated the global market for gastrointestinal drugs owing to the increasing digestive disorders, increasing healthcare expenditure, and presence of well-established healthcare sector in the region. According to the report published by the US Department of Health & Human Services, more than 15.3 million Americas were affected by ulcer in 2017, which is around 6.2% of total adult population. In 2018, it was estimated that Europe stood second in the gastrointestinal drugs market. The increasing awareness about digestive diseases, increasing investments in the healthcare industry in the region, and growing demand for efficient treatment solutions for gastrointestinal disorders is expected to drive the growth of the market. Germany held the largest share of the market for gastrointestinal drugs in the region.  


Asia-Pacific (APAC) is expected to witness the fastest growth in the gastrointestinal drugs market throughout the forecast period due to the rising geriatric population, presence of a large patient pool, and increasing government initiatives for the growth of the healthcare sector in the region. Countries in Asia-Pacific are adopting advanced treatment options, which in turn fuels the market growth in this region. Moreover, presence of developing countries, such as China, India, and Japan, is expected to drive the market growth in the region.


On the other hand, the Middle East & Africa is expected to hold the least share of the gastrointestinal drugs market due to the low economic development, especially in Africa.


Key Players


Some of the Key Players operating in the Global Gastrointestinal Drugs Market are Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi.


Market Segmentation


Global Gastrointestinal Drugs Market, by Drug Class



  • Acid Neutralizers

    • Antacids

    • H2 Antagonists

    • Proton Pump Inhibitors



  • Anti-inflammatory Drugs

  • Antidiarrheal and Laxatives

  • Antiemetic and Antinauseants

  • Biologics

  • Others


Global Gastrointestinal Drugs Market, by Route of Administration



  • Oral

  • Parenteral

  • Rectal


Global Gastrointestinal Drugs Market, by Application



  • Inflammatory Ulcerative Colitis

  • Irritable Bowel Syndrome

  • Crohn's Disease

  • Celiac Disease

  • Gastroenteritis

  • Others


Global Gastrointestinal Drugs Market, by Distribution Channel



  • Retail Pharmacies

  • Online Pharmacies

  • Hospital Pharmacies


Intended Audience



  • Gastrointestinal drugs manufacturing companies

  • Healthcare organizations

  • Healthcare providers

  • Government organizations

  • Biotechnology companies

  • Research and development (R&D) companies



Frequently Asked Questions (FAQ) :


Gastrointestinal drugs market valuation can touch USD 59,300 million by 2025.

Gastrointestinal drugs market is expected to exhibit a CAGR of 4.9% from 2019 to 2025.

Gastrointestinal drugs market is driven by the alarming cases of GI among the masses.

Presence of counterfeit drugs and high raw material costs can restrain the global gastrointestinal drugs market growth.

GlaxoSmithKline Plc., Janssen Biotech Inc., Johnson & Johnson, Valeant Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Takeda Pharmaceuticals, Allergan Plc, Bayer AG, Sanofi, AstraZeneca Plc, Novo Nordisk A/S, and AbbVie Inc. are major players of the global gastrointestinal drugs market.

Table of Contents:

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D and Designing

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Review

Chapter 6. Global Gastrointestinal Drugs Market, by Drug Class

6.1 Overview

6.2 Acid Neutralizers

6.2.1 Antacids

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.2.2 H2 Antagonists

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.2.3 Proton Pump Inhibitors

6.3 Anti-Inflammatory Drugs

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4 Antidiarrheal and Laxatives

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5 Antiemetic and Antinauseants

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.6 Biologics

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7 Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

Chapter 7. Global Gastrointestinal Drugs Market, by Route of Administration

7.1 Overview

7.2 Oral

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.3 Parenteral

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.4 Rectal

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

Chapter 8. Global Gastrointestinal Drugs Market, by Application

8.1 Overview

8.2 Inflammatory Ulcerative Colitis

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.3 Irritable Bowel Syndrome

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.4 Crohn's Disease

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.5 Celiac Disease

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.6 Gastroenteritis

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.7 Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

Chapter 9. Global Gastrointestinal Drugs Market, by Distribution Channel

9.1 Overview

9.2 Retail Pharmacies

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.3 Retail Pharmacies

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.4 Hospital Pharmacies

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

Chapter 10. Global Gastrointestinal Drugs Market, by Region

10.1 Overview

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Overview

11.2 Competitive Analysis

Chapter 12. Company Profile

12.1 Takeda Pharmaceticals

12.1.1 Company Overview

12.1.2 Products/Services Offered

12.1.3 Financial Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.1.6 Key Strategies

12.2 Allergan Plc

12.2.1 Company Overview

12.2.2 Products/Services Offered

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.2.6 Key Strategies

12.3 Novo Nordisk A/S

12.3.1 Company Overview

12.3.2 Products/Services Offered

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.3.6 Key Strategies

12.4 AstraZeneca Plc

12.4.1 Company Overview

12.4.2 Products/Services Offered

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.4.6 Key Strategies

12.5 AbbVie Inc.

12.5.1 Company Overview

12.5.2 Products/Services Offered

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

12.6 Valeant Pharmaceuticals Inc.

12.6.1 Company Overview

12.6.2 Products/Services Offered

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.6.6 Key Strategies

12.7 Johnson & Johnson

12.7.1 Overview

12.7.2 Products/Services Offered

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.7.6 Key Strategies

12.8 Bayer AG

12.8.1 Overview

12.8.2 Products/Services Offered

12.8.3 Financial Overview

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.8.6 Key Strategies

12.9 Boehringer Ingelheim GmbH

12.9.1 Overview

12.9.2 Products/Services Offered

12.9.3 Financial Overview

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.9.6 Key Strategies

12.10 GlaxoSmithKline Plc.

12.10.1 Overview

12.10.2 Products/Services Offered

12.10.3 Financial Overview

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.10.6 Key Strategies

12.11 Janssen Biotech Inc.

12.11.1 Overview

12.11.2 Products/Services Offered

12.11.3 Financial Overview

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.11.6 Key Strategies

12.12 Sanofi

12.12.1 Overview

12.12.2 Products/Services Offered

12.12.3 Financial Overview

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.12.6 Key Strategies

12.13 Others

Chapter 12 Appendix

12.1 References

12.2 Related Reports


LIST OF TABLES

Table 1 Global Gastrointestinal Drugs Market Synopsis, 2019–2025

Table 2 Global Gastrointestinal Drugs Market Estimates and Forecast, 2019–2025 (USD Million)

Table 3 Global Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 4 Global Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 5 Global Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 6 Global Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 7 Global Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)

Table 8 Americas: Gastrointestinal Drugs Market, by Region, 2018 and 2025

Table 9 Americas: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 10 Americas: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 11 Americas: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 12 Americas: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 13 North America: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)

Table 14 North America: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 15 North America: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 16 North America: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 17 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 18 US: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 19 US: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 20 US: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 21 US: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 22 Canada: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 23 Canada: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 24 Canada: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 25 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 26 Latin America: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 27 Latin America: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 28 Latin America: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 29 Latin America: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 30 Europe: Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)

Table 31 Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 32 Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 33 Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 34 Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 35 Western Europe: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)

Table 36 Western Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 37 Western Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 38 Western Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 39 Western Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 40 Eastern Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 41 Eastern Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 42 Eastern Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 43 Eastern Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 44 Asia-Pacific: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)

Table 45 Asia-Pacific: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 46 Asia-Pacific: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 47 Asia-Pacific: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 48 Asia-Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)

Table 49 Middle East & Africa: Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)

Table 50 Middle East & Africa: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)

Table 51 Middle East & Africa: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)

Table 52 Middle East & Africa: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)

Table 53 Middle East & Africa: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure of the Global Gastrointestinal Drugs Market

Figure 3 Market Dynamics of the Global Gastrointestinal Drugs Market

Figure 4 Global Gastrointestinal Drugs Market Share, by Drug Class, 2018 (%)

Figure 5 Global Gastrointestinal Drugs Market Share, by Drug Class, 2018 (USD Million)

Figure 6 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2018 (%)

Figure 7 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2018 (USD Million)

Figure 8 Global Gastrointestinal Drugs Market Share, by Application, 2018 (%)

Figure 9 Global Gastrointestinal Drugs Market Share, by Application, 2018 (USD Million)

Figure 10 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2018 (%)

Figure 11 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2018 (USD Million)

Figure 12 Global Gastrointestinal Drugs Market Share, by Region, 2018 (%)

Figure 13 Americas: Gastrointestinal Drugs Market Share, by Region, 2018 (%)

Figure 14 North America: Gastrointestinal Drugs Market Share, by Country, 2018 (%)

Figure 15 Europe: Gastrointestinal Drugs Market Share, by Region, 2018 (%)

Figure 16 Western Europe: Gastrointestinal Drugs Market Share, by Country, 2018 (%)

Figure 17 Asia-Pacific: Gastrointestinal Drugs Market Share, by Country, 2018 (%)

Figure 18 Middle East & Africa: Gastrointestinal Drugs Market Share, by Region, 2018 (%)

Figure 19 Global Gastrointestinal Drugs Market: Company Share Analysis, 2018 (%)

Figure 20 Takeda Pharmaceuticals: Key Financials

Figure 21 Takeda Pharmaceuticals: Segmental Revenue

Figure 22 Taked a Pharmaceuticals: Regional Revenue

Figure 23 Allergan Plc: Key Financials

Figure 24 Allergan Plc: Segmental Revenue

Figure 25 Allergan Plc: Regional Revenue

Figure 26 Novo Nordisk A/S: Key Financials

Figure 27 Novo Nordisk A/S: Segmental Revenue

Figure 28 Novo Nordisk A/S: Regional Revenue

Figure 29 AstraZeneca Plc: Key Financials

Figure 30 AstraZeneca Plc: Segmental Revenue

Figure 31 AstraZeneca Plc: Regional Revenue

Figure 32 AbbVie Inc.: Key Financials

Figure 33 AbbVie Inc.: Segmental Revenue

Figure 34 AbbVie Inc.: Regional Revenue

Figure 35 Valeant Pharmaceuticals Inc.: Key Financials

Figure 36 Valeant Pharmaceuticals Inc.: Segmental Revenue

Figure 37 Valeant Pharmaceuticals Inc.: Regional Revenue

Figure 38 Johnson & Johnson: Key Financials

Figure 39 Johnson & Johnson: Segmental Revenue

Figure 40 Johnson & Johnson: Regional Revenue

Figure 41 Bayer AG: Key Financials

Figure 42 Bayer AG: Segmental Revenue

Figure 43 Bayer AG: Regional Revenue

Figure 44 Boehringer Ingelheim GmbH: Key Financials

Figure 45 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 46 Boehringer Ingelheim GmbH: Regional Revenue

Figure 47 GlaxoSmithKline Plc.: Key Financials

Figure 48 GlaxoSmithKline Plc.: Segmental Revenue

Figure 49 GlaxoSmithKline Plc.: Regional Revenue

Figure 50 Janssen Biotech Inc.: Key Financials

Figure 51 Janssen Biotech Inc.: Segmental Revenue

Figure 52 Janssen Biotech Inc.: Regional Revenue

Figure 53 Sanofi: Key Financials

Figure 54 Sanofi: Segmental Revenue

Figure 55 Sanofi: Regional Revenue